CompanyNasdaqMinneapolis, MN
Celcuity Inc
Celcuity develops REVTORPYK (gedatolisib), a pan-PI3K and mTORC1/2 inhibitor for solid tumors.
8-KSep 30Latest SEC filing
Form DSep 23$130M sold
September 2026
Sign inSign inCelcuity develops REVTORPYK (gedatolisib), a pan-PI3K and mTORC1/2 inhibitor for solid tumors.